Castrate Resistance Prostate Cancer Clinical Trial
Official title:
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel treatment7,8.
Following Desmopressin/Docetaxel treatment subjects will be subjected to routine medical
oncology follow-up, including clinical appointments, laboratory and imaging workup as well as
additional Docetaxel therapy every 21 days as indicated.
An additional study clinical appointment with blood work will be organized two days post
Desmopressin/Docetaxel treatment. Furthermore, for detailed documentation of AEs during the
first 21 days following Desmopressin/Docetaxel therapy, subjects will be assessed weekly via
phone, and in person by the investigator/treating medical oncologist before the second dose
of docetaxel.
;